<DOC>
	<DOCNO>NCT01373151</DOCNO>
	<brief_summary>The purpose study determine effective dose BMS-945429 subject inadequate response Methotrexate treatment moderate severe Rheumatoid Arthritis .</brief_summary>
	<brief_title>Phase IIB Rheumatoid Arthritis Dose Ranging Study BMS-945429 Subjects Who Are Not Responding Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inadequate response Methotrexate Must take Methotrexate least 3 month minimal weekly dose least 15 mg stable dose 4 week prior randomization American College Rheumatology ( ACR ) global function status class 13 Minimum 6 swell 6 tender joint evidence synovitis least 1 hand wrist High sensitivity Creactive protein ( hsCRP ) â‰¥ 0.8 mg/dL Previously receive currently receive concomitant biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>